NSAID Panel Highlights Challenge Of Getting Comparative Safety Claim
This article was originally published in The Tan Sheet
Executive Summary
Does wide public health concern warrant flexibility in regulatory standards for safety claims? An advisory panel on cardiovascular risk of NSAIDs spotlights the dual challenge of accurately determining drug risks and communicating risks in informative way.
You may also be interested in...
NSAID Panel Could Give Naproxen Labeling Edge
FDA’s Arthritis and Drug Safety and Risk Management advisory committees on Feb. 10-11 will examine cardiovascular risk data for non-steroidal anti-inflammatory drugs, including meta-analyses indicating naproxen could have a better safety profile than other OTC ingredients ibuprofen and ketoprofen.
FDA Replaces Avandia REMS Distribution Restrictions With Prescriber Training
Comforted by the re-adjudicated RECORD results, agency directs rosiglitazone sponsors to provide training “based on the current state of knowledge” about the diabetes drug’s cardiovascular risk but eliminates the requirement that links drug access to provider, pharmacy and patient enrollment in the REMS.
Vioxx Withdrawal Could Have Impact On Post-Marketing Surveillance Methods
Fallout from the withdrawal of Vioxx (rofecoxib) will likely have an impact on post-marketing surveillance methods for COX-2 inhibitors and other drugs